Food Study of Ondansetron Tablets 24 mg and Zofran® Tablets 24 mg
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 28
- Registration Number
- NCT00648583
- Locations
- 🇺🇸
Gateway Medical Research, Inc., Saint Charles, Missouri, United States
Fasting Study of Ondansetron Tablets 24 mg and Zofran® Tablets 24 mg
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 28
- Registration Number
- NCT00649532
- Locations
- 🇺🇸
Gateway Medical Research, Inc., Saint Charles, Missouri, United States
Fasting Study of Lamotrigine Tablets 25 mg to Lamictal® Tablets 25 mg
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 27
- Registration Number
- NCT00650208
- Locations
- 🇺🇸
Kendle International Inc., Morgantown, West Virginia, United States
Fasting Study of Balsalazide Disodium Capsules 750 mg and Colazal® Capsules 750 mg
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 80
- Registration Number
- NCT00648531
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Fed Study of (Parlodel®) Bromocriptine Mesylate Capsules 5 mg
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 120
- Registration Number
- NCT00649168
- Locations
- 🇨🇦
MDS Pharma Services, Montreal, Quebec, Canada
Fasting Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 36
- Registration Number
- NCT00649129
- Locations
- 🇺🇸
Kendle International Inc., Morgantown, West Virginia, United States
Bioequivalence and Wear Study of Mylan Fentanyl Transdermal System 25 µg/h and Mylan Fentanyl Transdermal System
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 120
- Registration Number
- NCT00647842
- Locations
- 🇺🇸
Kendle International Inc., Morgantown, West Virginia, United States
Fasting Study of Doxycycline Monohydrate Tablets 100 mg and Adoxa Tablets 100 mg
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 35
- Registration Number
- NCT00649571
- Locations
- 🇺🇸
Kendle International Inc., Morgantown, West Virginia, United States
Fed Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mg
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 50
- Registration Number
- NCT00648622
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Fed Study of Oxybutynin Chloride Extended-release Tablets 10 mg and Ditropan XL® Tablets 10 mg
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 24
- Registration Number
- NCT00649727
- Locations
- 🇺🇸
Kendle International Inc., Morgantown, West Virginia, United States
© Copyright 2025. All Rights Reserved by MedPath